Reference is made to the stock exchange announcement from SoftOx Solutions AS
(the "Company") on 15 December 2021 regarding the successfully completed private
placement of 915,000 new shares. 

The share capital increase pertaining to the private placement of NOK 18,300
divided on 915,000 shares has today been registered in the Norwegian Register of
Business Enterprises (Nw: Foretaksregisteret).  

Following the share capital increase, the new share capital in the Company is
NOK 201,669.36 divided into 10,083,468 shares, each with a nominal value of NOK
0.02. 

The new shares will be listed and tradable on Euronext Growth Oslo from issuance
in the Central Securities Depository (VPS).

For further information, please contact:
CEO Geir Almås of SoftOx Solutions AS, or
CFO Kristine Rød of SoftOx Solutions AS
Mail: ir@soft-ox.com
Mobile: (+47) 948 59 599

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
BioTech company based in Oslo with the aim of helping to combat major threats to
human health, namely the emergence of antimicrobial resistance (AMR), biofilm
infections in chronic wounds and the spread of viruses. For more information on
SoftOx, visit www.soft-ox.com